Browse studies

Find your next paid study

2,801 recruiting studies matching your filters

Hypoxia and Heart Rate Variability

The purpose of this study is to evaluate how variations in oxygen demands may change heart electrical activity in individuals with and without oxygen dependenc…

Pulmonary Disease, Chronic ObstructiveHypoxia

Estimated

~$10 – $6,250

University of MiamiNCT05606406

The Vasculitis Pregnancy Registry (V-PREG)

The purpose of this study is to learn about the experience of women with vasculitis who become pregnant. In particular, the study will consist of several onlin…

VasculitisBehcet's DiseaseCNS Vasculitis+12 more

Estimated

~$10 – $750

University of PennsylvaniaNCT02593565

Observational

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

Lower attainment of cardiovascular health (CVH), indicated by the American Heart Association's Life's Simple 7 (LS7; physical activity, diet, cholesterol, bloo…

Cardiometabolic SyndromePhysical InactivityHypertension+9 more

Estimated

~$10 – $6,250

Ohio State UniversityNCT06055036

Observational

A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)

The XTRACT Registry is a prospective, single arm multicenter study on the use of on the Rotarex(TM) Rotational Excisional Atherectomy System.

Peripheral Arterial Disease(PAD)

Estimated

~$10 – $7,500

C. R. BardNCT07016698

Phase 3

An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to < 18 Years

This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ER…

Glycogen Storage Disease Type II Infantile Onset

Estimated

~$10 – $8,750

Amicus TherapeuticsNCT04808505

A Global Prospective Observational Registry of Patients With Pompe Disease

This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and inf…

Pompe Disease

Estimated

~$10 – $8,750

Amicus TherapeuticsNCT06121011

Phase 2

Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

Chronic Kidney Diseases

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT04500665

Phase 2

Pyridostigmine for the Treatment of Constipation in Parkinson Disease

Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There…

Parkinson DiseaseConstipation

Estimated

~$10 – $6,250

University of Vermont Medical CenterNCT05603715

Longitudinal Study of Urea Cycle Disorders

Urea cycle disorders (UCD) are a group of rare inherited metabolism disorders. Infants and children with UCD commonly experience episodes of vomiting, lethargy…

Brain Diseases, Metabolic, InbornAmino Acid Metabolism, Inborn ErrorsUrea Cycle Disorders

Estimated

~$10 – $1,125

Andrea GropmanNCT00237315

Phase 4

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

Parkinson Disease

Estimated

~$10 – $8,750

Impax Laboratories, LLCNCT06765668

Phase 1

Post-transplant Cyclophosphamide and Urinary-derived Human Chorionic Gonadotropin and Epidermal Growth Factor (uhCG/EGF) as Graft Versus Host Disease Prophylaxis for Mismatched Unrelated Donor Transplantation

So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human …

Graft Versus Host Disease

Estimated

~$10 – $6,250

Henry Ford Health SystemNCT04886726

Observational Study of the HemoCept Device During Right Heart Catheterization at Boulder Heart

The objective of this observational pilot study is to collect HemoCept device data from subjects undergoing diagnostic right heart catheterization (RHC) proced…

Pulmonary HypertensionCongestive Heart Failure(CHF)Valve Disease, Heart

Estimated

~$10 – $1,050

HemoCept Inc.NCT07224906